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Abstract
Introduction: It is very suggestive that diabetic foot is characterized by a pronounced inflammatory reaction and
the pathogenic significance of this inflammation has received little attention. On this basis the aim of our study
was to evaluate plasma levels of adiponectin, resistin and IL-6 in subjects with diabetic foot in comparison with
subjects without foot complications.
Materials and methods: We recruited 34 subjects with type 2 diabetes mellitus and foot ulceration hospitalized
for every condition related to diabetic disease, but not for new vascular events (group A). As controls we recruited
37 patients with type 2 diabetes mellitus without foot ulceration (group B) hospitalized for every condition related
to diabetic disease, but not for new vascular events. Adiponectin, Resistin and IL-6 serum levels were evaluated.
Results: Subjects of group A showed lower median plasma levels of adiponectin [7.7450 (4.47-12.17) μg/ml vs
8.480 (5.15-12.87) μg/ml], higher median plasma levels of IL-6 [3.21 (1.23-5.34) pg/ml vs 2.73 (1.24-3.97 pg/ml)] and
of resistin [3.860 (2.96-6.29 ng/ml) vs 3.690 (2.,37-6.5 ng/ml)].
Conclusion: Our study demonstrated that diabetic subjects with diabetic foot showed in comparison with
diabetics without diabetic foot higher IL-6 and resistin plasma levels, lower adiponectin plasma levels.
Introduction
In diabetes exists a complex interrelationship of various
inflammatory variables with metabolic disorders and
their effect on cardiovascular system.
Simplified explanation can be that inflammation
increases insulin resistance, which in turn leads to obe-
sity while perpetuating diabetes, high blood pressure,
prothrombotic state and dyslipidaemia [1]. Some studies
[2-4] have produced data suggesting an interplay
between hormones, cytokines and resistin.
Nevertheless, adiponectin, the most abundant adipocy-
tokine, was found to be decreased in conditions such as
obesity, type 2 diabetes, and coronary heart disease
(CHD) [5-7]. In this context, hypoadiponectinemia was
associated with low HDL-cholesterol (HDL-C) concen-
trations [8], decreased LDL particle size [6], and
increased markers of systemic inflammation [9].
Jeffcoate et al [10] al, suggested that an inflammatory
cascade through increased expression of proinflamma-
tory cytokines, including TNF-a and interleukin-1b
exist in diabetic foot, whereas no study, to our knowl-
edge, evaluated the role of adiponectin, resistin and
immune-inflammatory biomarkers such as inflammatory
cytokines in patients with diabetic foot in comparison
with diabetic subjects without foot complications.
On this basis the aim of our study was to evaluate
plasma levels of adiponectin, resistin and IL-6 in sub-
jects with diabetic foot in comparison with subjects
without foot complications.
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We recruited 34 subjects with type 2 diabetes mellitus
and foot ulceration (group A) hospitalized between 2006
and 2008 every for every condition related to diabetic dis-
ease (decompensated diabetes, hypoglycemia, clinical
revaluation for foot ulceration), but not for new vascular
events (group A) at the Internal and Specialist Medicine
Department and at Diabetic Foot Surgery Service of the
Policlinico P. Giaccone Hospital of Palermo. We also
recruited 37 patients with type 2 diabetes mellitus with-
out foot ulceration (group B) admitted to our department
for other causes between 2006 and 2008. The study was
carried out in accordance with the principles of the
Declaration of Helsinki as revised in 2001. All patients
gave informed consent to take part in this research
Foot ulcer was defined as a full-thickness skin defect
that required ≥14 days for healing [11].
Every subject with diabetic foot was matched for age
(± 3 years), sex, and cardiovascular risk factor preva-
lence with one control subject. Patients with inflamma-
tory or infectious diseases, autoimmune and rheumatic
diseases, cancer, haematological diseasesand severe renal
or liver failure, as well as those who were under treat-
ment with anti-inflammatory drugs, were excluded. We
also excluded patients with fever and recent venous
thromboembolism
A physical examination with emphasis on the lower
limbs was performed by research operators, who
assessed the presence of the following characteristics:
hammer/claw toe, Charcot deformity, hallux limitus,
prominent metatarsal heads, hallux valgus, bony promi-
nences, and ankle and halluxobility measured with a
goniometry.
Type 2 diabetes mellitus was determined using a clini-
cally based algorithm that considered age at onset, pre-
senting weight and symptoms, family history, onset of
insulin treatment, and history of ketoacidosis.
Hypertension was defined according to the 1993
World Health Organization criteria (systolic blood pres-
sure ≥140 mm Hg and/or diastolic blood pressure ≥90
mm Hg in subjects who are not taking antihypertensive
medication or antihypertensive treatment yet present on
admission) [12]. Hypercholesterolemia was defined as
total serum cholesterol ≥200 mg/dL and hypertriglyceri-
demia as total serum triglyceride ≥150 mg/dL on the
basis of the National Cholesterol Education Program-
Adult Treatment Panel III reports [13,14] that define
this cutoff for optimal total serum cholesterol and trigly-
ceride levels. All patients had blood pressure, serum glu-
cose, creatinine, serum uric acid, serum cholesterol
levels, serum triglyceride levels, and urinary albumin
excretion (UAE) values measured on admission to the
hospital.
The ankle-brachial index (ABI) was calculated as the
ratio of the ankle systolic pressure (defined as the higher
of the dorsalis pedis or posterior tibialis measurements)
divided by the higher brachial systolic pressure. Subjects
were classified as having PAD when they had an ABI
≤0.9 and/or when they had undergone a peripheral
arterial bypass or amputation [15].
Coronary artery disease was determined on the basis
of a history of physician-diagnosed angina, myocardial
infarction, or any previous revascularization procedure
assessed by a questionnaire. Cerebrovascular disease
(TIA/ischemic stroke) was assessed by history, specific
neurologic examination executed by specialists, and hos-
pital or radiological (brain computed tomography or
brain magnetic resonance) records of definite TIA or
stroke.
Neuropathy was detected by physical examination, and
medical history reviews of the patient.
Blood collection and laboratory analysis
Blood samples were obtained in the non-fasting state.
After 10 min of rest in the supine position, vital signs
were recorded and blood samples were collected from
the antecubital vein. EDTA-anticoagulated peripheral
blood was drawn from each patient within 12 h from
symptom onset. Serum and plasma were immediately
separated by centrifugation and stored in aliquots at
-80°C until analysis.
Adiponectin, Resistin and IL-6 serum levels were mea-
sured by enzyme-linked immunosorbent assay (ELISA)
method according to manufacturer suggestions. Regard-
ing to Adiponectin and Resistin determination, high
sensitivity kits (Biovendor) were used; IL-6 was deter-
mined by the Diaclone ELISA kit.
Regarding the sensitivity of Adiponectin test (Bioven-
dor), the analitical limit of detection was 0.6 microg/ml;
intra- and interassay coefficients of variation (%) were
4.1 and 4.0, respectively.
For Resistin assay (Biovendor), the analitical limit of
detection was 0.1 ng/ml; intra- and interassay CV (%)
were 2.8 and 5.1, respectively.
For IL-6 assay (Diaclone) the analitical limit of detec-
tion was 0.2 pg/ml; intra- and interassay CV (%) were
4.2 and 7.7, respectively.
Statistical Analysis
Results are expressed as median (lower Quartile ↔
upper Quartile) for continuous variables and percen-
tages for categorical data, with P <0 . 0 5c o n s i d e r e ds i g -
nificant. Analysis of normality was performed with the
Shapiro-Wilk W test. Non-normally distributed data
were logarithmically (Log10) transformed before analy-
sis. The relationship between IL-6, adiponectin and
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analyzed using nonparametric methods (Spearman
p correlations) after correction for age and gender.
Hazard ratios for the presence of foot ulcer were
determined by univariate and multivariate Cox propor-
tional hazards regression analyses with data presented as
hazard ratio with 95% confidence interval. Initial uni-
variate analyses identified demographic, clinical and
laboratory variables that independently predicted foot
ulcer presence.
According to sample size calculation a sample size of
30 patient-control pairs had 80% power at the 5% signif-
icance level to detect a 10% difference in selected bio-
marker plasma levels and arterial stiffness indexes
between control subjects and patients and between each
subtype of stroke.
Results
Baseline characteristic of subjects with diabetic foot in
comparison with subjects without diabetic foot are given
in table 1.
In group A 47.1% of subjects was male, while 41.7% of
subjects in group B were male. In group A 97.1% of
subjects had diabetes mellitus type 2, while in group B
type 2 diabetes was present in 97.2% of subjects.
Regarding the duration of diabetes of 20.6% of sub-
jects in group A vs 58.3% of subjects in group B could
be diabetic by <10 years, the 23.5% vs 30.6% for about
10 years, the 55.9% in group A vs 11.1% in group B by
>10 years.
The 11.8% of subjects in group A vs 8.3% of subjects
in group B was treated with diet, 8.8% vs 27.8% was in
treatment with oral anti-diabetic, 61.8% vs 27.8% was in
treatment with insulin. With regard of cardiovascular
risk factors, 20.6% of subjects in group A vs 25% of sub-
jects in group B was a smoker, 58.8% vs 69.4% had
hypertension, 41.2% vs 44.4% had dyslipidaemia, 59.4%
vs 36.1% had obesity and 64.7% vs 14.7% showed
microalbuminuria.
Regarding the prevalence of previous vascular morbid-
ity 29.4% of subjects in group A vs 25% of subjects in
group B had PAD, 50% vs 19.4% had ischemic heart dis-
ease, 41.17% vs 16.66% had a previous TIA or stroke,
4 4 . 1 %o fs u b j e c t si ng r o u pAv s3 6 . 1 %o fs u b j e c t si n
group B presented a chronic renal failure, while 73.52%
vs 38.8% had a neuropathy Subjects in group A also pre-
sented, in comparison with those in group B, increased
median levels of HbA1c [8 (7.28-9.40)% vs, 8.5 (6.10-
8.00)% ], CRP [4 (2,25-5.15) mg/dL vs 2, 25 (1.90-3.08)
mg/dL)], total cholesterol [215.50 (166.50-243,00) mg/
dL vs 204.00 (185.50 to 210.00 mg/dL)], LDL [121.70
(98.75-148.75) mg/dL vs 104.50 (78.00-123.00 mg/dL],
white blood cells [12675 (10775.00-14140.00 mg/dL vs
10700 (8850-12027.50) mg/dL ] (see table 2).
Finally, subjects of group A showed lower median
plasma levels of adiponectin [7.7450 (4.47-12.17) μg/ml
vs 8.480 (5.15-12.87) μg/ml], higher median plasma levels
of IL-6 [3.21 (1.23-5.34) pg/ml vs 2.73 (1.24-3.97 pg/ml)]
(see table 2) and higher median plasma levels of resistin
[5.160 (2.96-6.29 ng/ml) vs 3.690 (2.,37-6.5 ng/ml)](see
table 2).
Correlation analysis
There was a significant positive correlation, corrected
for age, and gender, between IL-6 and diabetes duration
Table 1 General and demographic variables in cases and
controls
pts with
diabetic
foot
pts without
diabetic
foot
p
n: 34 37 0.75
Age 66.7 ± 8.5 66.9 ± 7.9 0.027
Sex Male (n/%) 16 (47,1%) 15 (41,7%) 0.41
Diabetes duration
<10 yrs 7 (20,6%) 21 (58,3%) 0.027
=10 yrs 8 (23.5%) 11 (30.6%) 0.045
=20 yrs 19 (55.9) 4 (11.1%) <0.001
treatment Diet (n/%) 4 (11,8) 3 (8.3%) 0.65
Antidiabetici orali (n/%) 3 (8.8) 10 (27.8%) <0.001
Mixed (n/%) 6 (17.5) 13 (36,1%) <0.001
Insulin (n/%) 21 (61.8) 10 (27.8) <0.001
Smoking (n/%) 7 (20,6) 9 (25) 0.71
Hypertension (n/%) 20 (58,8) 25 (69.4) 0.041
Dyslipidaemia (n/%) 14 (41,2) 16 (44.4) 0.35
Obesity (n/%) 19 (55,9) 13 (36.1) 0.021
Chronic renal failure (n/%) 15 (44,1) 13 (36.1) 0.064
Mycroalbuminuria (n/%) 22 (64,7) 6 (14,7) <0.001
Retinopathty (n/%) 19 (55,9) 36 (100) <0.001
PAD (n/%) 10 (29.41) 9 (25) 0.54
CAD (n/%) 17 (50) 7 (19,4) <0.001
TIA/Stroke (n/%) 14 (41.17) 6 (16.66) 0.021
Other district atherosclerosis (n/
%)
28 (82.35 21 (58.33) <0.001
Artropathy (n/%) 11 (32,4%) 2 (5.6%) <0.001
Neuropathy (n/%) 25 (73.52) 14 (38.88%) <0.001
Diabetic foot grade
Grade 0 1 (2,9%) -
Grade 1 6 (17,6%) -
Grade 2 8 (23,5%) -
Grade 3 10 (29,4%) -
Grade4 4 (11,8%) -
Grade 5 1 (2,9%) -
Grade 6 4 (11,8%) -
Data are expressed as median and interquartile (lower and upper quartile)
PAD: peripheral artery disease; CAD: coronary artery disease
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dyslipidaemia (r = 0.25; p = 0.037), mycroalbuminuria (r
= 0.29; p < 0.05), retinopathy (r = 0.26; p = 0.021), PAD
(r = 0.30; p < 0.05) previous TIA/Stroke (r = 0.32;
p < 0.0001), neuropathy (r = 0.34; p < 0.0001, diabetic
foot grade, (r = 0.30; p < 0.0001)(see table 3).
There was a significant positive correlation corrected
for age and gender, between resistin and diabetes dura-
tion (r = 0.35;p < 0.05) hypertension (r = 0.22;p =
0.022), dyslipidaemia (r = 0.027; p = 0.041), BMI (r =
0.29; p = 0.022), mycroalbuminuria (r = 0.30; p < 0.05),
retinopathy (r = 0.26; p = 0.031), previous TIA/stroke
(r = 0.31; p < 0.0001), neuropathy (r = 0.33; p < 0.0001,
diabetic foot grade (r = 0.32 = < 0.0001)(see table 3).
There was a significant negative correlation between
adiponectin and diabetes duration (r = -0.37; p < 0.05);
hypertension (r = -0.32; p < 0.05), dyslipidaemia
(r = 0.39; p < 0.0001), retinopathy r = -0.28; p = 0.40);
PAD (r = 0.20; p = 0.021), previous TIA/Stroke (r =
-0.30; p = 0.021), neuropathy (r = -0.31; p > 0.0001),
diabetic foot grade (r = -0.29; p < 0.05)(see table 3).
Univariate analysis
On univariate analysis, age, diabetes duration, hypercho-
lesterolemia, hypertension, mycroalbuminuria, retino-
pathty, PAD, CAD, previous TIA/Stroke, Il-6 plasma
levels, resistin plasma levels were significantly associated
with diabetic foot presence, whereas adiponectin plasma
levels were negatively associated with diabetic foot (see
table 4)
Multivariate analysis
At multivariate analysis only age, diabetes duration,
hypercholesterolemia, hypertension, mycroalbuminuria,
retinopathty, PAD, IL-6 plasma levels, resistin plasma
levels were significantly associated with diabetic foot
presence, whereas adiponectin plasma levels were nega-
tively associated with diabetic foot (see table 4)
Conclusion
Our study demonstrated that diabetic subjects with dia-
betic foot showed in comparison with diabetics without
diabetic foot higher IL-6 and resistin plasma levels and
lower adiponectin plasma levels.
Resistin, although postulated to contribute to insulin
resistance, may also contribute to inflammatory responses.
Early investigations into the role of resistin as an inflam-
matory factor demonstrated that LPS (lipopolysaccharide)
up-regulated resistin expression in rat WAT, 3T3-L1 adi-
pocytes and human monocytes [16]. Although initial
rodent studies have produced discrepancies as to whether
Table 2 Laboratory variables in cases and controls
Diabetic foot
patients
Diabetics without
foot complications
p
HbA1c 8 (7.28-9.40) 6.85 (6.10-8.00) 0.018
CRP 4 (2.25-5.15) 2.25 (1.90-3.08) 0.041
Total cholesterol (mg/dl) 215.50 (166,50-243,00) 204.00 (185,50-210,00) 0.054
LDL cholesterol (mg/dl) 121.70 (98,75-148,75) 104.50 (78,00-123,00) 0.032
Tryglicerids (mg/dl) 160.50 (119,50-209,25) 180.50 (144,50-199,00) 0.012
Globuli bianchi 12.675 (10775,00-14140,00) 10.700 (8850,00-12027,50) 0.032
Adiponectin (μg/ml) 7.1450 (4.47-12.17) 8.480 (5.15-12.87) 0.022
Resistin (ng/ml) 5.160 (2.96-6.29) 3.290 (2.37-6.5) 0.021
IL-6 (pg/ml) 3.21 (1.23-5.34) 2.13 (1.24-3.97) 0.033
Demographic and anamnestic data are expressed as n° (percentage); HbA1c: Hemoglobin A1c; CRP: C-reactive protein; IL-6: Interleukin-6
Table 3 Correlation analysis between adiponectin,
resistin and IL-6 plasma levels and laboratory and clinical
variables in patients with diabetic foot
Adiponectin Resistin IL-6
Variable r p r p r p
Sex (male) 0.11 0.87 0.10 0.83 0.14 0.79
Diabetes duration -0.37 <0.05 0.33 <0.05 0.29 0.027
Smoking 0.12 0.67 0.09 0.12 0.09 0.12
Hypertension -0.32 <0.05 0.29 0.022 0.28 0.020
Dyslipidaemia -0.29 0.032 0.27 0.041 0.25 0.037
BMI -0.39 <0.0001 0.
29
0.022 0.10 0.20
Chronic renal
failure
0.11 0.23 0.17 0.81 0.19 0.88
Mycroalbuminuria 0.11 0.08 0.13 0.64 0.29 <0.05
Retinopathy -0.28 0.040 0.26 0.031 0.26 0.021
PAD 0.10 0.55 0.11 0.34 0.30 <0.05
CAD 0.14 0.77 0.11 0.67 0.11 0.67
Previous TIA/
Stroke
-0.29 <0.05 0.31 <0.0001 0.32 <0.0001
Neuropathy -0.31 <0.0001 0.33 <0.0001 0.34 <0.0001
Diabetic foot
grade
-0.29 <0.05 0.32 <0.0001 0.30 <0.0001
BMI: body mass index; PAD: peripheral artery disease; CAD: coronary artery
disease
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recent human studies have supported the concept of
inflammatory cytokine mediation of resistin [17,18].
Moreover, Osawa et al [19] reported that elevated
serum resistin concentration appears to be an indepen-
dent risk factor for ischemic stroke, especially lacunar
and atherothrombotic infarction in the general Japanese
population. In particular in this study authors showed
that the combination of high resistin and the presence
of either diabetes or hypertension increased the risk of
ischemic stroke.
Our findings concerning the higher plasma levels IL-6
plasma levels and resistin in diabetic subjects with foot
ulceration in comparison with diabetics without foot
complications may confirm this topics. A recent study by
Reilly and co-workers [20] suggested resistin as a meta-
bolic link between inflammation and atherosclerosis.
In contrast with resistin, adiponectin, known to
enhance insulin sensitivity and reduce atherosclerotic
plaques, suppressed a resistin-mediated rise in VCAM-1
and ICAM-1 [21].
Adiponectin levels can be assessed by either of three
variables: total adiponectin, HMWA and the SA index.
Recentlly Almeda-Valdes et al. [22] showed that total adi-
ponectin, HMWA and the SA index had similar utility
for the identification of the metabolic abnormalities. This
finding may stimulate the use of adiponectin in clinical
and epidemiological settings because the measurement of
total adiponectin is better standardized, cheaper and
more accessible than the other two approaches.
Hypoadiponectinaemia can be viewed as an early sign
of a complex cardiovascular risk factor predisposing to
the atherosclerosis process as well as a contributing
factor accelerating the progress of the atherosclerotic
plaque. Adiponectin exhibits anti-inflammatory and
atheroprotective actions in various tissues by suppres-
sing the expression of vascular adhesion molecules and
scavenger receptors, reducing the expression of the
inflammatory cytokine TNF-a, raising NO production
and suppressing the proliferation and migration of
smooth muscle cells [23].
To this date, two receptors have been identified that
mediate adiponectin’s actions in fatty-acid oxidation and
glucose uptake, namely ADIPOR1 and ADIPOR2 [24].
Very recently Halvatsiotis et al [25] have demonstrated
for the first time that a sequence variant in the intron 5
of the ADIPOR2, rs767870 among the eight studied, is
associated with cardiovascular disease in a population of
Greek individuals.
Our findings of lower median plasma levels of adipo-
nectin in subjects with diabetic foot could confirm this
issue. Furthermore we observed a significant negative
correlation between adiponectin plasma levels and some
cardiovascular risk factors such as hypertension, dyslipi-
daemia and clinical variables indicating previous cardio-
vascular morbidity such as previous TIA/Stroke and
incident vascular morbidity such as neuropathy, micro-
albuminuria and PAD and these findings further suggest
ap o s s i b l er o l eo fh y p o - a d i p o n e c t i n a e m i aa sap u t a t i v e
marker of cardiovascular morbidity both prevalent and
incident.
As several cytokines are also produced by adipose tis-
sue [26] it was postulated that an “adipo-vascular” axis
[27] may contribute to the increased risk of cardiovascu-
lar events in patients with type 2 diabetes. In patients
with diabetic foot this “adipo-vascular axis"expression in
Table 4 Cox regression analysis of clinical and laboratory variables associated with diabetic foot presence
Univariate analysis Multivariate analysis
Regression
coefficient
Hazard ratio
(95% CI)
P value Regression
coefficient
Hazard ratio
(95% CI)
P value
Age 0.69 2.32 (1.78-5.19) 0.021 0.49 2.12 (182-4.48) 0.031
Diabetes duration (y) 1.56 7.26 (3.80-13.87) <0.001 1.21 5.67 (2.70-8.34) <0.001
Hypercholesterolemia 0.59 1.55 (1.16-2.64) 0.21 0.44 0.87 (0.166-1.62) 0.42
Hypertension (n/%) 0.32 0.78 (1.70-4.34) 0.33 0.39 0.67 (0.30-1.12) 0.71
Obesity (n/%) 0.32 0.86 (0.31-1.23) 0.23 0.29 0.77 (0.42-0.98) 0.56
Chronic renal failure (n/%) 0.11 0.89 (0.53-1.31) 0.35 0.11 0.59 (0.21-0.89) 0.71
Mycroalbuminuria (n/%) 0.41 1.87 (1.32-3.51) 0.018 0.41 1.55 (1.11-2.99) 0.032
Retinopathty (n/%) 0.33 2.31 (1.78-4.78) 0.012 0.33 1.99 (1.45-3.24) 0.021
PAD (n/%) 0.61 3.5 (2.7-4.1) <0.005 0.59 2.9 (2.1-3.8) <0.005
CAD (n/%) 0.54 1.6 (1.4–2.7) 0.033 0.54 0.89 (0.5-1.1) 0.56
TIA/Stroke (n/%) 0.42 1.4 (1.21-2.09) 0.041 0.42 0.78 (0.33-0.91) 0.44
IL-6 1.12 4.8 (3.1-5.5) <0.005 0.98 3.6 (2.8-4.1) <0.005
Resistin 0.49 2.1 (1.4-3.9) 0.041 0.43 1.78 (1.4-2.9) 0.031
Adyponectin -0.29 -3.4 (-1.9-3.6) <0.001 -0.29 -2.9 (-1.5-3.4) <0.001
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levels of IL-6 could be linked to foot ulcers pathogenesis
by microvascular and inflammatory mechanisms.
Indeed recent studies suggest that adiponectin may
play a role in the modulation of inflammatory vascular
response by inhibiting the expression of adhesion mole-
cules on endothelial cells [28], inhibiting endothelial cell
NF-kB signaling [29], and suppressing macrophage func-
tion [30,31].
Other studies showed that adiponectin suppressed the
TNF-a-stimulated expression of E-selectin, VCAM-1
and ICAM-1 in human endothelial cells [28,29]. This
suggests further that adiponectin may be vasoprotective
and negatively modulate the atherogenic processes.
Recently Zietz et al [30] reported that low levels of
adiponectin are associated with low levels of HDL-cho-
lesterol and might represent an independent cardiovas-
cular risk factor, whereas high levels of adiponectin are
associated with high levels of HDL-cholesterol indicating
a protective risk profile.
Furthermore we observed significant either positive
(for IL-6 and resistin) and negative (for adiponectin)
correlations in subjects with diabetic foot between these
immuno-inflammatory and metabolic markers and some
clinical and laboratory variables and these correlation
furtherly underline the relationships with inflammatory
background.
Recently our group underlined [31] the role of diabetic
foot syndrome (DFS) to predict cardiovascular morbidity
in diabetic patients, even after correction for other well-
known cardiovascular risk factors. In our study both
univariate and multivariate analysis showed the predic-
tive positive role of resistin and IL-6 plasma levels and a
negative one of adyponectin towards diabetic foot
presence.
These findings furtherly underline the importance of
inflammatory and metabolic “milieu” such as cytokines
and adipose hormones in foot complications in diabetics
as already reported for other vascular complications of
diabetes [11,32,33].
A possible limitation our study is that we evaluated
only IL-6 as a inflammatory marker. Previous studies
have shown the relationship between inflammatory cyto-
kines and cardiovascular morbidity in diabetic patients.
T u t t l ee ta l[ 3 4 ]s h o w e dt h a tb o t hI L - 6a n dT N F - a are
chronically increased in diabetic women with and with-
out CVD compared to nondiabetic women. The additive
concentration of cytokines in diabetes and CVD sug-
gests a common inflammatory state in both diabetes
and CVD. Makino et al [32]. reported that serum levels
of TNF-a and vascular endothelial growth factor
(VEGF) were elevated in diabetic patients with microan-
giopathy and endothelial dysfunctio. Nevertheless owing
to the fact that the mechanisms that control expression
of different cytokines are often related and TNF-a sti-
mulates expression of IL-1 and IL-6, and IL-1 can
induce both IL-6 and TNF-a,t oe v a l u a t eo n l yI L - 6
expression in our patients with diabetic foot could be a
sufficient proof of immuno-inflammatory activation in
diabetic patients with foot complications.
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